AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14616411 — intervention group
Group type: EXPERIMENTAL
Intervention: voriconazole + azithromycin (500 mg once daily on days 12-14)
Number of subjects: 30
Study 14616411 — intervention group
Group type: COMPARATOR
Intervention: voriconazole + erythromycin
Number of subjects: 30
Study 14616411 — intervention group
Group type: COMPARATOR
Intervention: voriconazole + azithromycin
Number of subjects: 30
Study 11414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitor
Number of subjects: 40
Study 11414066 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 40
Study 8978338 — intervention group
Group type: EXPERIMENTAL
Intervention: Same day back-to-back colonoscopy
Number of subjects: 183
Study 7955820 — intervention group
Group type: EXPERIMENTAL
Intervention: Simendan (doses: 2 mg, 5 mg, 10 mg)
Number of subjects: 8
Study 7955820 — intervention group
Group type: EXPERIMENTAL
Intervention: Simendan (5 mg and 10 mg doses)
Number of subjects: 8
Study 3024863 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral captopril after 1 week of diuretic therapy (50 mg/day furosemide)
Number of subjects: 10
Study 3024863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3024863 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day furosemide
Number of subjects: 10
Study 31646707 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma renin activity (PRA) levels
Number of subjects: 618
Study 28279222 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised linear mixed modelling approach
Number of subjects: 3
Study 28279222 — intervention group
Group type: COMPARATOR
Intervention: Common analysis methods for stepped wedge trials
Number of subjects: 3
Study 28279222 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised linear mixed model
Number of subjects: 3
Study 28279222 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped wedge design with three steps
Number of subjects: 3
Study 26116237 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups made up of participants of a similar age and same gender
Number of subjects: 0
Study 26116237 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with similar-aged mixed gender participants
Number of subjects: 0
Study 26116237 — intervention group
Group type: COMPARATOR
Intervention: Mixed-aged mixed gender participants (control arm)
Number of subjects: 0
Study 23782471 — intervention group
Group type: EXPERIMENTAL
Intervention: Croí MyAction intervention group (n=27)
Number of subjects: 54
Study 23782471 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=27)
Number of subjects: 54
Study 21689270 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 795
Study 19846694 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI)
Number of subjects: 118
Study 19846694 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 118
Study 19846694 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) in patients with symptom onset of <2 years
Number of subjects: 118
Study 19846694 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF) in patients with symptom onset of <2 years
Number of subjects: 118
Study 19846694 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) in patients with symptom onset of <3 years
Number of subjects: 118
Study 19846694 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF) in patients with symptom onset of <3 years
Number of subjects: 118
Study 19846694 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) with high gene profile scores (>=2)
Number of subjects: 118
Study 19846694 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) with low gene profile scores (<2)
Number of subjects: 118
Study 16988064 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR-based outcomes
Number of subjects: 1094
Study 16988064 — intervention group
Group type: EXPERIMENTAL
Intervention: iGFR-based outcomes
Number of subjects: 1094
Study 16988064 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR and iGFR slopes
Number of subjects: 1094
Study 16988064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 1094
Study 12716240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated from 25 mg/day to 100 mg/day for 6 weeks)
Number of subjects: 23
Study 12716240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 23
Study 12716240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11055559 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (2 mg x kg(‐1) ingested 1 hour prior to heat exposure)
Number of subjects: 7
Study 11055559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ingested 1 hour prior to heat exposure)
Number of subjects: 7
Study 8612382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate tablet coingested with cimetidine (300 mg)
Number of subjects: 2
Study 8612382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate solution coingested with cimetidine (300 mg)
Number of subjects: 2
Study 8612382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate tablet coingested with famotidine (40 mg)
Number of subjects: 2
Study 1427946 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 33
Study 1427946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3882812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100
Study 3882812 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 100
Study 31282955 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver depression (9-item Patient Health Questionnaire score of ≥10)
Number of subjects: 663
Study 31282955 — intervention group
Group type: COMPARATOR
Intervention: Caregiver burden
Number of subjects: 663
Study 31282955 — intervention group
Group type: COMPARATOR
Intervention: Caregiver self-efficacy
Number of subjects: 663
Study 30600667 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic cystectomy combined with internal drainage (trial group)
Number of subjects: 56
Study 30600667 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic internal drainage (control group)
Number of subjects: 56
Study 30600667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (trial and control)
Number of subjects: 56
Study 27649614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (applied and re-applied up to 12 months)
Number of subjects: 107
Study 27649614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant (applied and re-applied up to 12 months)
Number of subjects: 107
Study 27649614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (applied and re-applied up to 12 months)
Number of subjects: 107
Study 27649614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 107
Study 24604360 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea 10% applied to the oral cavity 3-4 times per day for 3 months
Number of subjects: 38
Study 24604360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben, and 10% glycerol in distilled water)
Number of subjects: 38
Study 21755401 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marker results at baseline, 3 and 12 months
Number of subjects: 240
Study 21755401 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials every month and a membership in the National Osteoporosis Foundation
Number of subjects: 240
Study 21755401 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marker and educational information
Number of subjects: 240
Study 21755401 — intervention group
Group type: COMPARATOR
Intervention: Control, no information other than usual care
Number of subjects: 240
Study 21152005 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 194
Study 21152005 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate pathway model
Number of subjects: 194
Study 17333135 — intervention group
Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 14
Study 17333135 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 14
Study 17333135 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 14
Study 17333135 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 14
Study 15377650 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% O(2)
Number of subjects: 10
Study 15377650 — intervention group
Group type: COMPARATOR
Intervention: 21% O(2)
Number of subjects: 10
Study 12126242 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril (100 mg, three times daily)
Number of subjects: 945
Study 12126242 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (2 mg, three times daily)
Number of subjects: 945
Study 9886591 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (exact dosage and duration not specified)
Number of subjects: 288
Study 9886591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 288
Study 9226525 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with P:E ratio of 3.2 g/100 kcal
Number of subjects: 15
Study 9226525 — intervention group
Group type: COMPARATOR
Intervention: Formula with P:E ratio of 2.6 g/100 kcal
Number of subjects: 15
Study 1778279 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumetacin
Number of subjects: 2
Study 1778279 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 2
Study 7075196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered Lippes Loop D (LLD)
Number of subjects: 989
Study 7075196 — intervention group
Group type: COMPARATOR
Intervention: Standard Lippes Loop D (LLD)
Number of subjects: 989
Study 31917762 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopiclenol 0.2 mmol/kg
Number of subjects: 272
Study 31917762 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopiclenol 0.1 mmol/kg
Number of subjects: 272
Study 31917762 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopiclenol 0.05 mmol/kg
Number of subjects: 272
Study 31917762 — intervention group
Group type: COMPARATOR
Intervention: Gadopiclenol
Number of subjects: 272
Study 30914268 — intervention group
Group type: EXPERIMENTAL
Intervention: MALDITOF-MS
Number of subjects: 1005
Study 30914268 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostics
Number of subjects: 1005
Study 28667678 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT
Number of subjects: 60
Study 28667678 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study 27107668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and interpersonal psychotherapy adapted to BPD (IPT-BPD)
Number of subjects: 44
Study 27107668 — intervention group
Group type: COMPARATOR
Intervention: Single fluoxetine administered for 32 weeks
Number of subjects: 44
Study 23722581 — intervention group
Group type: EXPERIMENTAL
Intervention: PRINEO™ Skin Closure System
Number of subjects: 79
Study 23722581 — intervention group
Group type: COMPARATOR
Intervention: Intradermal sutures
Number of subjects: 79
Study 22516178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleet enema
Number of subjects: 130
Study 22516178 — intervention group
Group type: COMPARATOR
Intervention: No preoperative intestinal preparation (Control)
Number of subjects: 130
Study 20117503 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair (EVAR)
Number of subjects: 160
Study 20117503 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 160
Study 17443678 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin 1 mg/kg per day) and antithrombin (AT) supplementation
Number of subjects: 112
Study 17443678 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin (AT) alone
Number of subjects: 112
Study 15660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 919
Study 15660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 919
Study 15660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 919
Study 15660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 919
Study 15660024 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of atorvastatin
Number of subjects: 919
Study 15660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher starting doses of atorvastatin
Number of subjects: 919
Study 15660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (all doses)
Number of subjects: 919
Study 11844644 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT
Number of subjects: 72
Study 11844644 — intervention group
Group type: COMPARATOR
Intervention: LCT
Number of subjects: 72
Study 10077372 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable paper drape system
Number of subjects: 505
Study 10077372 — intervention group
Group type: COMPARATOR
Intervention: Reusable fabric drapes
Number of subjects: 505
Study 8644481 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 106
Study 8644481 — intervention group
Group type: COMPARATOR
Intervention: proglumide 1600 mg
Number of subjects: 106
Study 2042093 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage group (high-pressure suction drain in Morison's pouch for 48 hours)
Number of subjects: 479
Study 2042093 — intervention group
Group type: COMPARATOR
Intervention: Nondrainage group
Number of subjects: 479
Study 6987705 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine sulfate administration post-procedural
Number of subjects: 257
Study 6987705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 31557280 — intervention group
Group type: EXPERIMENTAL
Intervention: HK ratio (HKr)
Number of subjects: 11178
Study 31557280 — intervention group
Group type: EXPERIMENTAL
Intervention: PLP and HKr
Number of subjects: 11178
Study 31103829 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone access during examination
Number of subjects: 30
Study 31103829 — intervention group
Group type: COMPARATOR
Intervention: No smartphone access during examination
Number of subjects: 30
Study 26781645 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational Ciclesonide (CIC) 640 mcg via metered-dose inhaler at admission and 24 hours later
Number of subjects: 70
Study 26781645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic therapy)
Number of subjects: 70
Study 26781645 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational Ciclesonide (CIC)
Number of subjects: 70
Study 26422097 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg once daily for 2 weeks, then weight-adjusted doses for 4 weeks)
Number of subjects: 98
Study 26422097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 26422097 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (in posthoc analysis)
Number of subjects: 98
Study 26422097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in posthoc analysis)
Number of subjects: 98
Study 23312760 — intervention group
Group type: EXPERIMENTAL
Intervention: Low lutein (LL; 10 mg/d)
Number of subjects: 108
Study 23312760 — intervention group
Group type: EXPERIMENTAL
Intervention: High lutein (HL; 20 mg/d)
Number of subjects: 108
Study 23312760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein plus zeaxanthin (LZ; each 10 mg/d)
Number of subjects: 108
Study 23312760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 21177661 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics
Number of subjects: 3047
Study 21177661 — intervention group
Group type: COMPARATOR
Intervention: Control (no participatory ergonomics)
Number of subjects: 3047
Study 19342754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (100 microg)
Number of subjects: 20
Study 19342754 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (1 mg)
Number of subjects: 20
Study 17711714 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1 MspI polymorphism in smokers (CC genotype)
Number of subjects: 349
Study 17711714 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1 MspI polymorphism in low dose cigarette smoking group (CC and TC genotypes)
Number of subjects: 349
Study 17711714 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1 MspI polymorphism in high dose cigarette smoking group
Number of subjects: 349
Study 15285783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self-management training group intervention
Number of subjects: 273
Study 15285783 — intervention group
Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 273
Study 11473840 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 1% lidocaine
Number of subjects: 48
Study 11473840 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of 0.9% saline
Number of subjects: 48
Study 9517603 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 111
Study 9517603 — intervention group
Group type: COMPARATOR
Intervention: Conservative Therapy (CT)
Number of subjects: 111
Study 7996367 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (500 mg/kg)
Number of subjects: 753
Study 7996367 — intervention group
Group type: COMPARATOR
Intervention: Albumin (5 mg/kg)
Number of subjects: 753
Study 1971670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama breathing exercises using Pink City lung (PCL) exerciser
Number of subjects: 18
Study 1971670 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 18
Study 525751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol 600 mg infused immediately after anaesthesia
Number of subjects: 100
Study 525751 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 31889231 — intervention group
Group type: EXPERIMENTAL
Intervention: migalastat (150 mg every other day)
Number of subjects: 7
Study 31889231 — intervention group
Group type: COMPARATOR
Intervention: ERT (agalsidase alfa 0.2 mg/kg or agalsidase beta 1.0 mg/kg)
Number of subjects: 7
Study 30925197 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning fasting (0 kcal until 12:00 pm)
Number of subjects: 0
Study 30925197 — intervention group
Group type: COMPARATOR
Intervention: Daily breakfast (> 700 kcal by 11:00 am)
Number of subjects: 0
Study 30925197 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 27077263 — intervention group
Group type: EXPERIMENTAL
Intervention: ULF-TENS applied for 20 minutes
Number of subjects: 20
Study 27077263 — intervention group
Group type: EXPERIMENTAL
Intervention: ULF-TENS applied for 40 minutes
Number of subjects: 20
Study 27077263 — intervention group
Group type: EXPERIMENTAL
Intervention: ULF-TENS applied for 60 minutes
Number of subjects: 20
Study 27077263 — intervention group
Group type: COMPARATOR
Intervention: ULF-TENS applied for 20 to 40 minutes
Number of subjects: 20
Study 25766731 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-assisted MI intervention
Number of subjects: 159
Study 25766731 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 159
Study 24145042 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridial collagenase ointment (CCO)
Number of subjects: 48
Study 24145042 — intervention group
Group type: COMPARATOR
Intervention: Saline moistened gauze (SMG)
Number of subjects: 48
Study 21343172 — intervention group
Group type: EXPERIMENTAL
Intervention: novel endoscopic lens cleaning device
Number of subjects: 40
Study 21343172 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 40
Study 19651562 — intervention group
Group type: EXPERIMENTAL
Intervention: NB‐UVB phototherapy 3 times a week for 24 weeks
Number of subjects: 44
Study 19651562 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1% cream b.i.d. for 24 weeks
Number of subjects: 44
Study 19651562 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment b.i.d. for 24 weeks
Number of subjects: 44
Study 17149529 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Dependence Scale (ADS)
Number of subjects: 1372
Study 17149529 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS subscales reflecting psychoperceptual or psychophysical withdrawal
Number of subjects: 1372
Study 15111848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - 40 mg of enoxaparin
Number of subjects: 849
Study 15111848 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) - 5000 IU heparin
Number of subjects: 849
Study 11569894 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 20
Study 11569894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9588369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low airloss hydrotherapy
Number of subjects: 116
Study 9588369 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 116
Study 8148303 — intervention group
Group type: COMPARATOR
Intervention: Single injection of 20 mL of an amide‐ester solution (1% lidocaine/0.2% tetracaine) with epinephrine 1:200,000
Number of subjects: 50
Study 8148303 — intervention group
Group type: EXPERIMENTAL
Intervention: Double injection of two 10 mL injections of the same solution
Number of subjects: 50
Study 2900659 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids for at least 18 months
Number of subjects: 165
Study 2900659 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange and prednisone
Number of subjects: 165
Study 2900659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic agents (27% of patients)
Number of subjects: 165
Study 2900659 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 50, gastrointestinal problems, cardiomyopathy, renal signs
Number of subjects: 165
Study 31315670 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral erector spinae block (20 mL 0.25% levobupivacaine)
Number of subjects: 80